ReviewFrontiers in pharmacology2025
Targeting lipophagy and nuclear receptors in metabolic-associated fatty liver disease: insights from traditional Chinese medicine.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- p-Coumaric acid inhibits hepatocellular carcinoma through promoting ROS accumulation.Medical oncology (Northwood, London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic associated fatty liver disease (MAFLD) represents a globally prevalent chronic hepatic disorder hallmarked by excessive lipid accumulation within hepatocytes. This condition can progressively deteriorate to cirrhosis and hepatocellular carcinoma, thereby imposing a substantial healthcare burden. Numerous laboratory studies confirm that drugs targeting the nuclear receptor (NR)-lipophagy axis exhibit preventive and therapeutic potential for MAFLD. However, most remain confined to animal and cell models, and no specific MAFLD therapies are clinically available. In contrast, traditional Chinese medicine (TCM) has garnered considerable interest due to its unique theoretical framework and clinical efficacy in MAFLD management. PURPOSE: This article systematically reviews existing herbal compounds, extracts, and active metabolites that target the NR-lipophagy interaction for MAFLD treatment. It aims to facilitate the development of low-side-effect herbal formulations and offer valuable insights for future research on the NR-lipophagy axis.
methodSearch terms including "MAFLD", "nuclear receptor", "lipophagy", "Compound Traditional Chinese Medicine", "active metabolites", "natural products", and "disease" were combined for literature retrieval.
resultAs modulators of pleiotropic NRs, certain herbal metabolites mimic endogenous ligands to exert regulatory lipolysis effects-synergistically modulating lipid metabolism, mitigating oxidative stress, and suppressing inflammation during MAFLD intervention. Herbal compound preparations modulate the NR-lipophagy axis
conclusionTCM (including herbal compound preparations, extracts, and active metabolites) exerts therapeutic effects on MAFLD by inducing lipophagy through diverse pharmacological mechanisms and NR-associated signaling pathways. These agents emerge as promising focal points for MAFLD basic research and potential candidates for MAFLD drug development, offering reduced side effects and enhanced therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.